Prospective associations of hemoglobin A1c and c-peptide with risk of diabetes-related cancers in the Cancer Prevention Study-II Nutrition Cohort
- PMID: 36712480
- PMCID: PMC9881454
- DOI: 10.1158/2767-9764.crc-22-0082
Prospective associations of hemoglobin A1c and c-peptide with risk of diabetes-related cancers in the Cancer Prevention Study-II Nutrition Cohort
Abstract
Self-reported type 2 diabetes mellitus (T2DM) is a risk factor for many cancers, suggesting its pathology relates to carcinogenesis. We conducted a case-cohort study to examine associations of hemoglobin A1c (HbA1c) and c-peptide with cancers associated with self-reported T2DM. This study was drawn from a prospective cohort of 32,383 women and men who provided blood specimens at baseline: c-peptide and HbA1c were assessed in 3,000 randomly selected participants who were cancer-free-at-baseline and an additional 2,281 participants who were cancer-free-at-baseline and subsequently diagnosed with incident colorectal, liver, pancreatic, female breast, endometrial, ovarian, bladder, or kidney cancers. Weighted-Cox regression models estimated hazards ratios (HRs) and 95% confidence intervals (CI), adjusted for covariates. C-peptide was associated with higher risk of liver cancer (per standard deviation (SD) HR: 1.80; 95%CI: 1.32-2.46). HbA1c was associated with higher risk of pancreatic cancer (per SD HR: 1.21 95%CI 1.05-1.40) and with some suggestion of higher risks for all-cancers-of-interest (per SD HR: 1.05; 95%CI: 0.99-1.11) and colorectal (per SD HR: 1.09; 95%CI: 0.98-1.20), ovarian (per SD HR: 1.18; 95%CI 0.96-1.45) and bladder (per SD HR: 1.08; 95%CI 0.96-1.21) cancers. Compared to no self-reported T2DM and HbA1c <6.5% (reference group), self-reported T2DM and HbA1c <6.5% (i.e., T2DM in good glycemic control) was not associated with risk of colorectal cancer, whereas it was associated with higher risks of all-cancers-of-interest combined (HR: 1.28; 95%CI: 1.01-1.62), especially for breast and endometrial cancers. Additional large, prospective studies are needed to further explore the roles of hyperglycemia, hyperinsulinemia, and related metabolic traits with T2DM-associated cancers to better understand the mechanisms underlying the self-reported T2DM-cancer association and to identify persons at higher cancer risk.
Conflict of interest statement
Conflict of interest statement The authors declare that they have no conflicts of interest. The authors declare no potential conflicts of interest.
Similar articles
-
Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia.Cochrane Database Syst Rev. 2018 Oct 29;10(10):CD012661. doi: 10.1002/14651858.CD012661.pub2. Cochrane Database Syst Rev. 2018. PMID: 30371961 Free PMC article.
-
Serum glucose and hemoglobin A1C levels at cancer diagnosis and disease outcome.Eur J Cancer. 2016 May;59:90-98. doi: 10.1016/j.ejca.2016.02.018. Epub 2016 Mar 25. Eur J Cancer. 2016. PMID: 27017290 Free PMC article.
-
Incident Type 2 Diabetes Duration and Cancer Risk: A Prospective Study in Two US Cohorts.J Natl Cancer Inst. 2021 Apr 6;113(4):381-389. doi: 10.1093/jnci/djaa141. J Natl Cancer Inst. 2021. PMID: 33225344 Free PMC article.
-
Hyperglycemia and chronic liver diseases on risk of hepatocellular carcinoma in Chinese patients with type 2 diabetes--National cohort of Taiwan Diabetes Study.Int J Cancer. 2015 Jun 1;136(11):2668-79. doi: 10.1002/ijc.29321. Epub 2014 Dec 1. Int J Cancer. 2015. PMID: 25387451
-
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.Cochrane Database Syst Rev. 2019 Dec 3;12(12):CD008558. doi: 10.1002/14651858.CD008558.pub2. Cochrane Database Syst Rev. 2019. PMID: 31794067 Free PMC article.
Cited by
-
Prospective Analysis of Circulating Biomarkers and Ovarian Cancer Risk in the UK Biobank.Cancer Epidemiol Biomarkers Prev. 2024 Oct 2;33(10):1347-1355. doi: 10.1158/1055-9965.EPI-24-0319. Cancer Epidemiol Biomarkers Prev. 2024. PMID: 39007864 Free PMC article.
-
A burden of proof study of the effects of exposure to high fasting plasma glucose on the risk of seven types of cancer.Sci Rep. 2025 Aug 7;15(1):28859. doi: 10.1038/s41598-025-13045-9. Sci Rep. 2025. PMID: 40775253 Free PMC article.
-
Prediabetes and the risk of breast cancer: a meta-analysis.Front Oncol. 2023 Sep 18;13:1238845. doi: 10.3389/fonc.2023.1238845. eCollection 2023. Front Oncol. 2023. PMID: 37790752 Free PMC article.
-
Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical view.J Endocrinol Invest. 2024 Dec;47(12):2915-2928. doi: 10.1007/s40618-024-02417-z. Epub 2024 Jun 27. J Endocrinol Invest. 2024. PMID: 38935200 Free PMC article. Review.
-
Increased colorectal cancer risk in prediabetes: A meta-analysis.World J Diabetes. 2025 May 15;16(5):103403. doi: 10.4239/wjd.v16.i5.103403. World J Diabetes. 2025. PMID: 40487609 Free PMC article.
References
-
- Luo S, Li J-Y, Zhao L-N, Yu T, Zhong W, Xia Z-S, et al. . Diabetes mellitus increases the risk of colorectal neoplasia: an updated meta-analysis. Clin Res Hepatol Gastroenterol 2016;40:110–23. - PubMed
-
- Campbell PT. The role of diabetes and diabetes treatments in colorectal cancer mortality, incidence, and survival. Curr Nutr Rep 2013;2:37–47.
-
- De Bruijn KMJ, Arends LR, Hansen BE, Leeflang S, Ruiter R, Van Eijck CHJ. Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br J Surg 2013;100:1421–9. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous